Curis (NASDAQ: CRIS) is one of 212 public companies in the “Biotechnology & Medical Research” industry, but how does it contrast to its peers? We will compare Curis to similar businesses based on the strength of its valuation, dividends, institutional ownership, earnings, risk, profitability and analyst recommendations.
Volatility & Risk
Curis has a beta of 1.86, suggesting that its share price is 86% more volatile than the S&P 500. Comparatively, Curis’ peers have a beta of 1.54, suggesting that their average share price is 54% more volatile than the S&P 500.
This table compares Curis and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Valuation and Earnings
This table compares Curis and its peers top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||NetIncome||Price/Earnings Ratio|
|Curis||$7.53 million||-$60.41 million||-3.12|
|Curis Competitors||$220.75 million||-$39.68 million||-63.40|
Curis’ peers have higher revenue and earnings than Curis. Curis is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
Institutional and Insider Ownership
44.7% of Curis shares are held by institutional investors. Comparatively, 48.6% of shares of all “Biotechnology & Medical Research” companies are held by institutional investors. 4.1% of Curis shares are held by company insiders. Comparatively, 14.0% of shares of all “Biotechnology & Medical Research” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
This is a summary of recent ratings and target prices for Curis and its peers, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Curis presently has a consensus price target of $6.50, suggesting a potential upside of 316.67%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 13.69%. Given Curis’ stronger consensus rating and higher probable upside, research analysts clearly believe Curis is more favorable than its peers.
Curis peers beat Curis on 7 of the 12 factors compared.
Curis, Inc. is a biotechnology company seeking to develop and commercialize drug candidates for the treatment of cancers. The Company’s drug candidate is CUDC-907, an orally-available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes. CUDC-907 is an oral, dual inhibitor of Class I and II HDAC, as well as Class I PI3K enzymes. CA-170 is an oral small molecule drug candidate that is designed to selectively target programmed death ligand-1 (PDL1) and V-domain Ig suppressor of T-cell activation (VISTA) immune checkpoint proteins, both of which independently function as negative regulators of immune activation. CA-4948 is an oral small molecule drug candidate that is designed to inhibit the Interleukin-1 receptor-associated kinase 4 (IRAK4) kinase, which is a transducer of toll-like receptor or certain interleukin receptor signaling pathways.
What are top analysts saying about Curis Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Curis Inc. and related companies.